Compare MXC & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXC | NNVC |
|---|---|---|
| Founded | 1972 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8M | 21.2M |
| IPO Year | 1995 | 2008 |
| Metric | MXC | NNVC |
|---|---|---|
| Price | $9.00 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.9K | ★ 172.3K |
| Earning Date | 02-10-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ 30.65 | 10.00 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,705,235.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.57 | ★ N/A |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $5.98 | $0.85 |
| 52 Week High | $16.48 | $2.23 |
| Indicator | MXC | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 52.38 |
| Support Level | $8.34 | $0.86 |
| Resistance Level | $9.65 | $1.07 |
| Average True Range (ATR) | 0.60 | 0.06 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 5.96 | 60.71 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.